Skip to main content

Table 4 Statistical comparison between pre-treatment and post-treatment parameters in glycemic non-improved patients

From: Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control

  Pre-treatment (no = 53) Post-treatment (no = 53) P value
Hemoglobin (g/dL)a 12.98 ± 1.34 12.25 ± 1.44 0.001
Leukocytes (× 103/μL cells)a 6.53 ± 1.67 6.98 ± 1.72 0.038
Platelets (× 103/μL cells)a 223.57 ± 50.09 228.91 ± 51.77 0.150
Albumin (g/dL)a 4.25 ± 0.42 4.28 ± 0.39 0.249
Bilirubin, total (mg/dL)a 0.81 ± 0.15 0.67 ± 0.16 0.001
INRa 1.29 ± 1.36 1.07 ± 0.06 0.253
AST (IU/L)a 50.65 ± 24.36 22.38 ± 7.83 0.001
ALT (IU/L)a 55.71 ± 27.48 23.87 ± 9.43 0.001
Creatinine (mg/dL)a 1.02 ± 0.86 0.93 ± 0.18 0.404
HbA1c (%)a 8.17 ± 0.58 7.91 ± 0.79 0.001
AFP (ng/mL)a 7.08 ± 5.01 6.43 ± 4.09 0.012
FIB-4b scorea 1.89 ± 0.85 1.38 ± 0.47 0.001
  1. aMean ± SD. Glycemic improved group: ≥ 1% reduction of baseline HbA1c levels at SVR. Non-glycemic improved group: < 1% reduction of baseline HbA1c levels at SVR
  2. AFP Alpha-fetoprotein, ALT Alanine transaminase, AST Aspartate transaminase, bFIB-4 score = [age 3AST]/[platelets 3 ALT1/2], INR international normalized ratio, HbA1c glycated hemoglobin